The Next Evolution of the JOST KKS Automatic Coupling System: the KKS-U Connector
In April 2021 JOST introduced the revolutionary KKS automatic coupling system. It enables the driver to couple and uncouple the semi-trailer via remote control – automatically, safely and quickly. Climbing out of the cabin, cranking down the landing gear and manually connecting the spiral cable, air and brake connections are all a thing of the past. Now JOST presents the latest development of the KKS: the KKS-U Connector which is retrofittable to existing trailers that already are on the roads of this world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005001/en/
The KKS-U Connector is easily retrofittable to trailers that are already in use. (Photo: JOST)
Coupling and uncoupling a trailer is still a lengthy, expensive and hazardous procedure. The truck driver has to be aware of many different things, each of which are time-consuming and pose a hazard to health and safety. As the global market leader for fifth wheel couplings and landing gears, JOST is providing a smart solution for the future of coupling with its KKS automatic coupling system. The KKS 42 fifth wheel coupling, Modul E-Drive electric landing gear, sensor coupling system, 3-sensors, LubeTronic automatic lubrication system, KKS remote control and the ISO 13044-2-certified KKS connector all combine to form an innovative system for the coupling process.
KKS-U Connector retrofittable to existing trailers
Until now the KKS was a solution for mixed fleets and new trailers. JOST has now further developed the system and is introducing the new KKS-U Connector to the market. Fitted to the underside of the trailer, the KKS-U Connector is an alternative installation variant and enables fleet operators to equip existing trailers easily with the KKS. It connects all the mechanical, electric, and air connections between the truck and trailer, eliminating the need for the standard vulnerable air, electrics and ABS/EBS spiral lines.
The KKS-U basically consists of three parts: the reliable future-proof and ISO 13044-2 compliant standard wedge, the steel spring and the cable box. The newly designed wedge has the familiar KKS connector installed inside. It is attached to the high-quality JOST king pin and rotates around it when cornering. The steel spring encases the supply lines for air, brake and electric safely and reliably. The supply lines are safely stowed in the KKS cable box and are fed into the steel spring when cornering.
“The KKS-U Connector is a unique solution for all trailers that are already in operation. Due to a particularly straightforward installation, they can be effortlessly equipped with the KKS system. No modifications to the trailer chassis are necessary”, said Andreas Jakubin, Product Manager KKS. “Thus, the KKS-U contributes to further savings in time and expenses as well as avoidance of accidents.”
Advantages of the KKS: more efficiency and safety for truck drivers
Using the KKS automatic coupling system can cut the time required to change a trailer by up to 50 percent, as there is no need to manually crank the landing gear, connect the supply lines or open the fifth wheel coupling. The KKS significantly reduces the total costs for each circuit, with savings of up to 50 percent possible during the coupling and uncoupling process. It is particularly well suited for transport companies which perform coupling processes often and drive short distances, such as those in on-site transport, as the time saved here really pays off financially. Another application is the transport of goods where safety plays a key role, such as hazardous goods, as the sensor monitoring guarantees a high level of security against trailer losses and incorrect coupling. The KKS is also an ideal solution for transport between production sites and logistics facilities. Errors or damage caused during the coupling process are eliminated completely thanks to monitoring through the KKS remote control. For example, the Modul E-Drive landing gear is always fully retracted automatically. Moreover, the KKS reduces the probability of trailer losses due to erroneous operation, damage and occupational accidents to virtually zero.
Furthermore, the KKS makes all the physically demanding tasks of the coupling process a thing of the past, as well as ensuring that this process is no longer dependent on the weather or time of day and significantly reducing stress. A standard pneumatic cylinder opens the fifth wheel coupling effortlessly, even when the tractor-trailer is twisted. The automatic coupling process means that the driver does not have to climb in and out of the cab as often, nor climb onto the catwalk between truck and semi-trailer – two factors that significantly reduce the potential for injury. These benefits mean the KKS opens new possibilities for a more diverse driver pool; as such, JOST is providing an answer to demographic change and the lack of specialist workers.
More information on the KKS and KKS-U Connector online at: kks-futurenow.com
About JOST:
JOST is a world-leading producer and supplier of safety-critical systems for the commercial vehicle industry. Under the umbrella brand of JOST, the comprehensive range of products is broken down into systems for applications on the road and in agriculture:
The JOST brand includes fifth wheel couplings, landing gears, ball bearing turntables, king pins and container locks as well as components for alternating systems. Truck and trailer axles are also sold under the JOST brand. The tradition-steeped ROCKINGER brand comprises the core components of towing hitches, drawbar eyes and drawbars for transporters and trucks. TRIDEC offers steering systems and axle suspensions for trailers.
ROCKINGER products are also used in agricultural applications. Quicke has been part of the JOST family since February 2020 and specialises in agricultural front loaders and equipment.
JOST currently employs over 3,600 staff worldwide and has sales and production sites in over 20 countries and on all five continents. JOST has been listed on the Frankfurt Stock Exchange. Further information on JOST can be found here: www.jost-world.com
Press images can be found here: https://www.jost-world.com/en/corporate/mediacenter/press-releases.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005001/en/
Contact information
Christin Zindritsch
Manager Marketing Communications
christin.zindritsch@jost-world.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
